A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Bucci Laser Vision Institute

Status and phase

Completed

Phase 4

Conditions

Post Operative Anterior Chamber Inflammation (Flare)

Treatments

Drug: Ketorolac Tromethamine 0.45%

Drug: Bromfenac 0.09%

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01023724

2009-11-06 1

Details and patient eligibility

About

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects must be 18 years of age or older
Scheduled for cataract surgery by phacoemulsification
Subject must be willing to comply with all study requirements and be willing to give informed consent

Exclusion criteria

Any subject that has a history of uveitis or active iritis
Subject can have no previous intraocular surgery with the exception of refractive surgery. but not within 6 months
No ocular use of prostaglandins within 2 weeks of surgery
Use of oral, injectable or topical steroids,nonsteroidal anti-inflammatory drugs (NSAIDs) or immunosuppressants within 14 days prior to surgery
Contraindications to NSAIDs
Active ocular infection